eli lilly retatrutide trials orforglipron oral GLP-1 phase 3 weight loss trial New Phase 3 retatrutide data
Description
PMID: 34347962
The SURPASS trial series spans five major trials with combined enrollment exceeding 10,000 participants, establishing the most comprehensive GLP-1 agonist evidence base in existence
These patents extend the patent protection far beyond the term of the original patented invention for these drugs
10.1634/THEONCOLOGIST.2010-0256 38 LargM
Retatrutide products sold by Peptides Direct Australia are supplied strictly for laboratory research purposes only
Second, it allows clinicians to identify the minimum effective dose for each individual
